RheumNow Podcast – Pounds of Prevention (3.5.2021)

Save

Dr. Jack Cush reviews nearly a dozen news reports and journal articles from the past week on RheumNow.com.

Baricitinib Therapy in Covid-19 Pneumonia

Save

The NEJM has published the results of the ACCT-2 Study,  a double-blind, randomized, placebo-controlled trial evaluating baricitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2, plus remdesivir in hospitalized adults with Covid-19. The primary outcome was the time to recovery.

Paucity of Effectiveness Research on Telemedicine in RA

Save

A systematic review of telehealth in delivering equivalent care in rheumatoid arthritis (RA) patients demonstrates there is limited evidence that virtual RA care is equivalent to conventional face-to-face (F2F) care; thus despite current widespread use there is a great need for credible well-desi

NEJM: Interleukin-6 Inhibition in Critically-Ill COVID-19

Save

The pendulum and jury are wavering with regard to the benefits of interleukin-6 receptor antagonists in COVID-19; the current NEJM reports the results of a study favoring such biologic therapy in in critically ill COVID-19 patients.

RWCS Highlights - Day 3

Save

Today I’ve included some research and clinical pearls as well as fodder for your post COVID-19 dinner party or trivia night!  Enjoy!

Psoriatic Arthritis: 2020 Year in Review: with Drs. Alexis Ogdie, Artie Kavanaugh, and Eric Ruderman

ACR Promotes New COVID-19 Vaccine Clinical Guidance for Rheumatic Patients

Save

The American College of Rheumatology has published a draft guidance on the use of COVID-19 vaccination in rheumatic disease and musculoskeletal disease (RMD) patients, based on the efforts of the North American Task force.

Comorbidity and Drugs Drive COVID-19 Severity and Survival in Rheumatic Disease

Save

While comorbidities are associated with severe COVID-19 infection, it appears they also influence severity and survival in rheumatic disease (RMD), according to a a French cohort study,

IVIg in MIS-C

Save

Among children with multisystem inflammatory syndrome (MIS-C), treatment with IVIG and methylprednisolone vs IVIG alone was associated with a more favorable fever course. MIS-C is a rare but serious pediatric condition associated with COVID-19 where different body parts can become inflamed, inclu

RheumNow Podcast – Tofacitinib Safety Concerns (2.5.2021)

Save

Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.

Hydroxychloroquine Fails to Prevent COVID-19

Save

There is a preponderance and mounting evidence that hydroxychloroquine (HCQ) is ineffective in COVID-19 infection; and now the NEJM reports a the results of a trial where HCQ given as post-COVID exposure therapy failed to prevent SARS-CoV-2 infection or symptomatic Covid-19 in healthy pe

Adverse Events with Anti-malarials during the COVID Pandemic

Save

For a variety of reasons, the use of anti-malarials (chloroquine and hydroxychloroquine) rose dramatically in the pandemic; notable was the lack of proven benefit and the dramatic risk in reported adverse drug reactions (ADRs) associated with these drugs being used to treat SARS-CoV-2.

Consults in Cars

Save

In this episode of Dialing for Doctors (AKA Tales of Telehell), we will consider a growing subset of telehealth seekers connecting from their cars.

I don’t mean they are driving to the clinic, or driving to a virtual care center.